Inventor · disambiguated record
Stefan Steidl
Also filed as: STEIDL STEFAN
8 granted patents·22 pending applications·54 citations·filing 2006–2024
83Inventor score
Top patents by PatentIndex Score
30 records- 0192US7867495B2Anti-GM-CSF antibodies and uses thereforMORPHOSYS AG·Filed 2006·Granted Jan 11, 2011·25 cites·54 claims
- 0289US9023351B2Anti-mesothelin antibodies and uses thereofKAHNERT ANTJE·Filed 2008·Granted May 5, 2015·28 cites·5 claims
- 0377US2024417455A1Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2024·Application pending·0 cites
- 0477US2024424012A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0577US2024366756A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0676US10913792B2Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2018·Granted Feb 9, 2021·1 cites·7 claims
- 0771US2021347879A1Anti-gm-csf antibodiesMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 0870US11028165B2Nucleic acid encoding anti-GM-CSF antibodiesMORPHOSYS AG·Filed 2019·Granted Jun 8, 2021·0 cites·14 claims
- 0962US2021130451A1Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 1062US2020352975A1Combinations and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1161US2020353077A1Combinations and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1260US10377820B2Methods of treatment using anti-GM-CSF antibodiesMORPHOSYS AG·Filed 2016·Granted Aug 13, 2019·0 cites·8 claims
- 1358US2014255427A1Combination therapy with an anti - cd19 antibody and a nitrogen mustardAMERSDORFFER JUTTA·Filed 2012·Application pending·0 cites
- 1458US2014227277A1Combination therapy with an anti-CD19 antibody and a purine analogAMERSDORFFER JUTTA·Filed 2012·Application pending·0 cites
- 1557US2024228654A9Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejectionMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1656US2024109977A1Anti-cd38 antibodies and their usesMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1755US10005840B2Method for treatment of osteoarthritis with C-Fms antagonistsUNIV MELBOURNE·Filed 2015·Granted Jun 26, 2018·0 cites·2 claims
- 1854US2018237531A1Method for the treatment of pain and osteoarthritis with c-fms antagonistsUNIV MELBOURNE·Filed 2018·Application pending·0 cites
- 1953US9243066B2Use of M-CSF antibodies in the treatment of osteoarthritis or painSTEIDL STEFAN·Filed 2012·Granted Jan 26, 2016·0 cites·4 claims
- 2052US2015246969A1Treatment for rheumatoid arthritisMORPHOSYS AG·Filed 2013·Application pending·0 cites
- 2151US2018258181A1Anti-mesothelin antibodies and uses thereofBAYER IP GMBH·Filed 2018·Application pending·0 cites
- 2250US9751939B2Anti-GM-CSF antibodiesSTEIDL STEFAN·Filed 2010·Granted Sep 5, 2017·0 cites·5 claims
- 2348US2010291078A1Proteinaceous binding molecules comprising purification tags or inert variable domainsMORPHOSYS AG·Filed 2009·Application pending·0 cites
- 2448US2022144965A1Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune diseaseMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 2547US2011110944A1Anti-alk1 antibodies and uses thereofMORPHOSYS AG·Filed 2009·Application pending·0 cites
- 2646US2009137002A1Anti ephb4 antibodies and antibody fragmentsPETRUL HEIKE·Filed 2008·Application pending·0 cites
- 2743US2009081207A1High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicityMENRAD ANDREAS·Filed 2007·Application pending·0 cites
- 2842US2015259433A1Anti-mesothelin antibodies and uses thereofBAYER IP GMBH·Filed 2015·Application pending·0 cites
- 2936US2012116059A1Treatment For M Treatment For Multiple SclerosisSTEIDL STEFAN·Filed 2010·Application pending·0 cites
- 3034US2014234298A1Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereofSTEIDL STEFAN·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefan Steidl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →